Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of nucleotide-binding oligomerization domain-like receptor protein in the treatment of Zika virus infection

A technology of oligomerization domain and receptor protein, which can be applied to antiviral agents, peptide/protein components, medical preparations containing active ingredients, etc., and can solve the problems of Zika virus prevention and treatment.

Active Publication Date: 2020-06-30
广东龙帆生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no reports on the preventive and therapeutic effects of NLRP3 itself on Zika virus (ZIKV)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of nucleotide-binding oligomerization domain-like receptor protein in the treatment of Zika virus infection
  • Application of nucleotide-binding oligomerization domain-like receptor protein in the treatment of Zika virus infection
  • Application of nucleotide-binding oligomerization domain-like receptor protein in the treatment of Zika virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The application of a nucleotide-binding oligomerization domain-like receptor protein 3 (NOD-like receptors, NLRP3) in the preparation of a drug for treating or preventing Zika virus (ZIKV) infection, the steps of which are:

[0032] (1) Clone NLRP3 gene (NLRP3 preparation): using the total mRNA extracted from THP-1 (Human acute monocytic leukemia cell line) cells as a template, amplify the total cDNA by reverse transcription PCR, and then use the total cDNA as a template The template was amplified with specific primers to obtain the NLRP3 gene fragment. Primers are as follows:

[0033] P1 (forward primer): 5'-CGCGGATCCATGAAGATGGCAAGCACCCGC-3'BamHI

[0034] P1 (reverse primer): 5'-CCGCTCGAGCTACCAAGAAGGCTCAAAGAC-3' XhoⅠ

[0035] The NLRP3 gene was cloned into the pTAC (purchased from Cresbo) promoter of the vector pGEX-6p-1 (purchased from YRgene) by BamHI and XhoI digestion and ligation to obtain the expression vector pGEX-6p-1-NLRP3 of NLRP3 .

[0036] (2) Acquisiti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses application of nucleotide binding and oligomerization domain-like receptor protein in the treatment of Zika virus infection drugs. The steps include: A, evaluating activity ofthe nucleotide binding and oligomerization domain-like receptor protein e to resist Zika virus; B, extracting total mRNA in THP-1 cells to form a template; performing reverse PCR (polymerase chain reaction) amplification to obtain total cDNA; performing Bam H I and Xho I enzymatic cutting and connection so as to clone NLRP3 gene to pTAC starter of the carrier pGEX-6p-1; C, selecting the single strain colony, introducing LB liquid culture with ampicillin, performing NLRP3 expression, purifying and concentrating by means of affinity chromatography to obtain NLRP3 lyophilized liquid; D, adding aprotein into the cells, and detecting ZIKV NS5 mRNA level and protein level; NLRP 3 is in-vivo composed inertial expression and has no side and effective actions for the human body; pathogenesis of the NLRP3 refers to inhibit virus copy by changing signals in cells, anti-virus mechanisms are diverse, and viruses and drug resistance are avoided.

Description

technical field [0001] The present invention relates to the field of antiviral drugs, more specifically to the use of a nucleotide-binding oligomerization domain-like receptor protein 3 (NOD-like receptors, NLRP3) in the preparation of drugs for treating or preventing Zika virus (ZIKV) infection application. Background technique [0002] Zika virus (ZIKV) is an arbovirus transmitted through the bite of Aedes mosquitoes. ZIKV was first discovered in 1947 in a febrile rhesus monkey in the Zika Forest of Uganda. Despite serological evidence that ZIKV is widespread worldwide, few human infections with ZIKV have been documented. Until 2007, a large-scale outbreak of Zika virus occurred on Yap Island, Federated States of Micronesia. 75% of the residents on this island in the South Pacific-like area were infected by the virus. This is the first time that ZIKV has shown its potential. Transmissibility and pathogenicity. The second large-scale outbreak of ZIKV occurred in French ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/17A61P31/14
CPCA61K38/177A61P31/14Y02A50/30
Inventor 吴建国王文标邬开朗刘映乐李耿刘芳谭秋萍罗震
Owner 广东龙帆生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com